Valuation: Candel Therapeutics, Inc.

Market Cap 631M 567M 523M 474M 887M 59.96B 898M 6.27B 2.49B 31.43B 2.37B 2.32B 99.67B P/E 2026 *
-5.84x
P/E 2027 * -7.09x
Enterprise Value 631M 567M 523M 474M 887M 59.96B 898M 6.27B 2.49B 31.43B 2.37B 2.32B 99.67B EV / Sales 2026 *
-
EV / Sales 2027 * 15.1x
Free-Float
85.21%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Candel Therapeutics, Inc.

1 day+5.91%
1 week-4.51%
Current month-20.98%
1 month-25.14%
3 months-17.17%
6 months+31.16%
Current year+46.02%
1 week 7.7
Extreme 7.7
8.79
1 month 7.7
Extreme 7.7
11.25
Current year 4.44
Extreme 4.44
14
1 year 4.35
Extreme 4.35
14
3 years 0.66
Extreme 0.66
14.6
5 years 0.66
Extreme 0.66
14.6
10 years 0.66
Extreme 0.66
14.78
Manager TitleAgeSince
Chief Executive Officer 66 01/09/2020
Director of Finance/CFO 41 12/01/2024
Chief Tech/Sci/R&D Officer 57 12/09/2022
Director TitleAgeSince
Director/Board Member 80 01/09/2017
Director/Board Member 66 01/09/2020
Chairman 70 15/07/2021
Date Insider Type Main position Quantity % Market Cap. Importance
9/30/26 A Free

Director

380 0.0005%
9/30/26 A Free

Chairman

2,189 0.0029%
9/30/26 A Free

Director

1,325 0.0017%
Change 5-day change 1-year change 3-year change Capi.($)
+5.91%-4.51%+52.78%+816.87% 631M
-3.10%-4.19%+32.67%+59.47% 63.48B
+0.33%+0.33%+10.16%+78.07% 54.55B
+0.16%+1.73%+9.89%+102.10% 53.59B
-0.75%+1.38%+24.89%+50.91% 44.75B
-1.30%-4.80%+16.05%+114.76% 41.62B
+1.26%-5.26%+221.12%+900.64% 39.91B
-0.74%-4.46%+11.00%+44.65% 32.47B
+1.11%+15.18%+60.27%+49.33% 26.7B
+3.45%-6.32%+25.90%-8.36% 23.36B
Average +0.65%-1.52%+46.47%+220.84% 38.11B
Weighted average by Cap. -0.30%-1.28%+42.96%+156.39%

Financials

2026 *2027 *
Net sales - 41.92M 37.62M 34.74M 31.5M 58.87M 3.98B 59.6M 416M 165M 2.09B 157M 154M 6.62B
Net income -102M -91.14M -84.16M -76.32M -143M -9.65B -144M -1.01B -401M -5.06B -381M -373M -16.03B -92.33M -82.86M -76.51M -69.38M -130M -8.77B -131M -917M -364M -4.6B -347M -339M -14.58B
Net Debt - -
Projected Income Statement - Annual - Candel Therapeutics, Inc.
Logo Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a BLA-ready clinical-stage biopharmaceutical company focused on developing off-the-shelf multimodal biological immunotherapies that elicit an individualized, systemic antitumor immune response to help patients fight cancer. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.
Employees
55
Date Price Change Volume
27/10/26 $8.250 +5.91% 928,461
26/10/26 $7.790 -2.99% 849,302
23/10/26 $8.030 -4.18% 1,184,816
22/10/26 $8.380 +0.12% 762,579
21/10/26 $8.370 -3.13% 1,102,647
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Candel Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.250USD
Average target price
22.11USD
Spread / Average Target
+168.01%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Candel Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. CADL Stock